SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Contributed by: Business Wire

Logo

Business Wire logo

Images

Illustrative example: cancer associated fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)
Illustrative example: cancer associated fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)
Business Wire embedded0

Tags

Health Technology
Other Health
Radiology
Pharmaceutical
Oncology
General Health
Hospitals
Neurology
Clinical Trials
Cardiology
Science
Biotechnology
Other Science
Health
Research
SOFIE Biosciences

More Like This

Business Wire logo

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

PR Newswire associated0

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Business Wire logo

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

PR Newswire associated0

Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

PR Newswire associated0

Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations